FR20C1054I1 - Derives de quinolines et compositions pharmaceutiques de ces derives - Google Patents

Derives de quinolines et compositions pharmaceutiques de ces derives

Info

Publication number
FR20C1054I1
FR20C1054I1 FR20C1054C FR20C1054C FR20C1054I1 FR 20C1054 I1 FR20C1054 I1 FR 20C1054I1 FR 20C1054 C FR20C1054 C FR 20C1054C FR 20C1054 C FR20C1054 C FR 20C1054C FR 20C1054 I1 FR20C1054 I1 FR 20C1054I1
Authority
FR
France
Prior art keywords
derivatives
pharmaceutical compositions
quinoline
quinoline derivatives
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1054C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613158A external-priority patent/GB0613158D0/en
Priority claimed from GB0613159A external-priority patent/GB0613159D0/en
Priority claimed from GB0613156A external-priority patent/GB0613156D0/en
Priority claimed from GB0613160A external-priority patent/GB0613160D0/en
Priority claimed from EP06117129A external-priority patent/EP1878722A1/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR20C1054I1 publication Critical patent/FR20C1054I1/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR20C1054C 2006-06-30 2020-11-12 Derives de quinolines et compositions pharmaceutiques de ces derives Active FR20C1054I1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0613158A GB0613158D0 (en) 2006-06-30 2006-06-30 Organic compounds
GB0613159A GB0613159D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613156A GB0613156D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613160A GB0613160D0 (en) 2006-06-30 2006-06-30 Organic Compounds
EP06117129A EP1878722A1 (en) 2006-07-13 2006-07-13 Quinolinone derivatives and their pharmaceutical compositions
EP07819899A EP2044025B1 (en) 2006-06-30 2007-07-02 Quinolinone derivatives and their pharmaceutical compositions

Publications (1)

Publication Number Publication Date
FR20C1054I1 true FR20C1054I1 (fr) 2020-12-25

Family

ID=38610531

Family Applications (2)

Application Number Title Priority Date Filing Date
FR20C1054C Active FR20C1054I1 (fr) 2006-06-30 2020-11-12 Derives de quinolines et compositions pharmaceutiques de ces derives
FR20C1063C Active FR20C1063I1 (fr) 2006-06-30 2020-12-08 Derives de quinolines et compositions pharmaceutiques de ces derives

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR20C1063C Active FR20C1063I1 (fr) 2006-06-30 2020-12-08 Derives de quinolines et compositions pharmaceutiques de ces derives

Country Status (27)

Country Link
US (2) US8198450B2 (ja)
EP (1) EP2044025B1 (ja)
JP (1) JP5253392B2 (ja)
KR (1) KR101402398B1 (ja)
CN (1) CN101479245B (ja)
AU (1) AU2007264946B2 (ja)
BR (1) BRPI0713951B8 (ja)
CA (1) CA2654801C (ja)
CY (3) CY1113733T1 (ja)
DK (1) DK2044025T3 (ja)
ES (1) ES2396987T3 (ja)
FR (2) FR20C1054I1 (ja)
HK (1) HK1127597A1 (ja)
HR (1) HRP20121074T1 (ja)
HU (2) HUS2000043I1 (ja)
IL (1) IL195796A (ja)
LT (2) LTC2044025I2 (ja)
MA (1) MA30540B1 (ja)
MX (1) MX2008016542A (ja)
MY (1) MY150468A (ja)
NO (3) NO341709B1 (ja)
NZ (1) NZ573292A (ja)
PL (1) PL2044025T3 (ja)
PT (1) PT2044025E (ja)
SI (1) SI2044025T1 (ja)
WO (1) WO2008000839A1 (ja)
ZA (1) ZA200809948B (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012332A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
KR20120120453A (ko) 2007-09-05 2012-11-01 화이자 리미티드 Ｎ4-(2,2-다이플루오로-4ｈ-벤조〔1,4〕옥사진-3-온)-6-일〕-5-플루오로-ｎ2-〔3-(메틸아미노카보닐메틸렌옥시)페닐〕2,4-피리미딘다이아민의 지나포에이트 염
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US20150374623A1 (en) 2013-03-14 2015-12-31 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
EP3347345B1 (en) 2015-09-29 2019-07-31 Inke, S.A. Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one l-tartrate
CN110724095B (zh) * 2019-09-12 2023-06-09 上海方予健康医药科技有限公司 一种茚达特罗乙酸盐的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05202301A (ja) * 1991-08-29 1993-08-10 Yamamoto Chem Inc ２−アニリノ−３−メチル−６−（Ｎ−ｎ−ブチル−Ｎ−シクロヘキシルアミノ）フルオランの結晶変態、その製造方法及びこの結晶変態を含有する記録材料
EP0688871A3 (en) * 1994-06-24 1998-07-08 Quest International B.V. Preparation of phytosphingosine derivative
FR2777279B1 (fr) * 1998-04-08 2004-08-13 Hoechst Marion Roussel Inc Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0127430D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
US7417051B2 (en) 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
TWI324150B (en) 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
PE20050211A1 (es) 2003-04-02 2005-04-27 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
DE602004019198D1 (de) 2003-04-04 2009-03-12 Novartis Ag Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
AU2006227300B2 (en) 2005-03-21 2012-02-02 Eli Lilly And Company Imidazopyridazine compounds
GB0511065D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
EP1910369A1 (en) 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors

Also Published As

Publication number Publication date
US8198450B2 (en) 2012-06-12
KR101402398B1 (ko) 2014-06-03
JP5253392B2 (ja) 2013-07-31
CN101479245B (zh) 2013-05-22
KR20090023651A (ko) 2009-03-05
ES2396987T3 (es) 2013-03-01
AU2007264946A1 (en) 2008-01-03
MA30540B1 (fr) 2009-06-01
NO2020041I1 (no) 2020-11-23
CA2654801C (en) 2014-08-19
IL195796A (en) 2016-03-31
FR20C1063I1 (fr) 2021-01-22
BRPI0713951A2 (pt) 2012-12-04
IL195796A0 (en) 2009-09-01
PT2044025E (pt) 2012-12-17
NO20090312L (no) 2009-01-28
LTC2044025I2 (lt) 2022-10-10
PL2044025T3 (pl) 2013-02-28
CY2020038I1 (el) 2021-03-12
HUS2000043I1 (hu) 2020-12-28
NO2020044I1 (no) 2020-12-07
CY1113733T1 (el) 2016-06-22
DK2044025T3 (da) 2013-01-14
AU2007264946B2 (en) 2011-01-20
MX2008016542A (es) 2009-01-19
CN101479245A (zh) 2009-07-08
CY2020038I2 (el) 2021-03-12
HUS2000053I1 (hu) 2020-12-28
NO341709B1 (no) 2018-01-02
CY2020041I1 (el) 2021-03-12
CY2020041I2 (el) 2021-03-12
CA2654801A1 (en) 2008-01-03
WO2008000839A1 (en) 2008-01-03
BRPI0713951B1 (pt) 2019-08-13
EP2044025A1 (en) 2009-04-08
EP2044025B1 (en) 2012-10-03
JP2009541455A (ja) 2009-11-26
SI2044025T1 (sl) 2013-01-31
HK1127597A1 (en) 2009-10-02
HRP20121074T1 (hr) 2013-01-31
NZ573292A (en) 2011-03-31
ZA200809948B (en) 2009-05-25
LTPA2020535I1 (lt) 2020-12-28
US20090325912A1 (en) 2009-12-31
BRPI0713951B8 (pt) 2021-05-25
US20120316142A1 (en) 2012-12-13
MY150468A (en) 2014-01-30
LTPA2020538I1 (lt) 2021-01-11

Similar Documents

Publication Publication Date Title
FR20C1063I1 (fr) Derives de quinolines et compositions pharmaceutiques de ces derives
IL199853A (en) Converged history of 5-Hydroxy-Admentil-2-Reindeer and Pharmaceutical Preparation containing them
BRPI0923836A2 (pt) Composições farmacêuticas orais contendo opióide e métodos
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
BRPI0906980A2 (pt) Composição de derivados e maleatados
SMT201700084B (it) Associazioni antineoplastiche di 4-anilino-3-cianochinoline e capecitabina
DE602007010981D1 (de) Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
BRPI0918759A2 (pt) ácidos 2-aril-propiônicos e derivados e composições farmacêuticas contendo os mesmos
EP2188259A4 (en) PROCESS FOR THE PREPARATION AND ADMINISTRATION OF CHINOLINE DERIVATIVES AS ANTICROBIAL AGENTS
IL206594A (en) The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations
CR10229A (es) Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
BRPI1007092A2 (pt) "derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas, método para prevenção ou tratamento de doença e método de produção de derivados de hidroxamato"
IL193211A (en) Derivatives of Indzol-Troaril and pharmaceutical preparations containing them
BRPI0813100A2 (pt) Preparação sólida farmacêutica e método de produção da mesma
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
FR2940911B1 (fr) Formulation pour l'administration par voie trans-muqueuse buccale de molecules antalgiques et/ou anti-spasmodiques
DK2152699T3 (da) Quinolon-forbindelse og farmaceutisk sammensætning
BRPI0914971A2 (pt) composições farmacêuticas que contêm fármaco antibiótico de fluoroquinolonas
BRPI0922286A2 (pt) composto de quinolona e composição farmacêutica.
UY33128A (es) Derivados de piridinona y composiciones farmacéuticas de los mismos
DK2099759T3 (da) Antibakterielle chinolinderivater
ZA200806725B (en) New citrate salt of an indole derivative and its pharmaceutical use
PT2220047E (pt) Derivados de quinolina, composições farmacêuticas que os contêm e sua utilização
BRPI0816239A2 (pt) Derivados terapêuticos de quinolina e naftaleno